Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis
Author:
Affiliation:
1. Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
2. Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province, China
Abstract
Publisher
Future Medicine Ltd
Subject
Health Policy
Link
https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0041
Reference27 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. WHO. World Cancer Report 2014 (2014). www.who.int/cancer/publications/WRC_2014/en/
3. Cancer statistics in China, 2015
4. Global cancer statistics, 2012
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review;Health Economics Review;2024-07-05
2. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib;Medical Science Monitor;2024-06-14
3. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments;Digestive and Liver Disease;2023-12
4. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11
5. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma;PLOS ONE;2023-10-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3